Skin Oncology Firm MedC Biopharma Launches Private Placement Offering on DealSquare

Distributed by Business Wire
4th December 2020

Clinical-stage company is focused on innovation in skin health worldwide

TORONTO–(BUSINESS WIRE)–$MEDCB #dealmaker—MedC Biopharma Corporation (“MedC”), a science-driven company that develops, produces and delivers innovative skin oncology medication worldwide, has announced the launch of its $3 million private placement offering using the DealSquare platform, powered by NEO and DealMaker technology.

A clinical-stage biopharmaceutical company, MedC ($MEDCB) develops and commercializes cannabinoid and other natural compound-containing products for use in the consumer, veterinary, medical skin, and general health markets. The company has already developed two drugs toward clinical trials for CTCL – Skin (Cutaneous) T-cell Lymphoma and Cutaneous Leishmaniasis, both of which are recognized as orphan conditions with unmet needs, and as markets with huge potential. MedC is developing its own proprietary red sea-algae “Algel” gel-based products, with a variety of applicable uses for skin health and wellness, and is also pursuing opportunities in veterinary medication and pet health, specifically oncology and inflammation-related indications (an estimated $400 million annual market).

MedC’s campaign marks the first capital raise through the joint service offering between DealSquare and DealMaker. DealSquare, powered by NEO, is a fully automated and centralized platform allowing capital raisers to publish their private placement opportunities, dealers to complete their due diligence, and advisors and investors to electronically subscribe to a deal. DealMaker provides the back-office technology, transaction engine, and electronic signature functionality for investors submitting orders electronically, compliantly, globally. Together, DealSquare, NEO, and DealMaker provide MedC with the smoothest transaction experience and broadest reach of capital market participants.

“The launch of our private offering leveraging the joint service capabilities of these reputable platforms marks a significant step towards MedC taking its place amongst industry leaders that are determined to legitimize and deliver the health benefits of cannabinoids to the global community,” remarked Dr. Owen Van Cauwenberghe, President of MedC. “Our tireless efforts and commitment to substantiated medical and health claims for these products will ensure that their benefits will be available to all those in need. We are fortunate to be able to take advantage of the combined DealSquare, NEO, and DealMaker offering.”

MedC’s listing on DealSquare, combined with the technology of DealMaker, creates an opportunity for investors who believe there is a global need to mature and legitimize the cannabis and cannabis-related health and medical market, by supporting the development of products that deliver health and wellness benefits. With the funds raised from the campaign, MedC is targeting international expansion, initially across Canada and Australia, with plans to launch in Europe, UK, Asia, and Latin America shortly thereafter. It will also expand its product offering with new lines for different markets and multiple dose formats. There will be a strong focus on research and development of high value market products, as well as regulatory work, thus enabling MedC to further enhance its product offering.

“We welcome MedC as our first partner in the joint initiative we have launched with DealMaker,” said Peter-Paul Van Hoeken, Managing Director of DealSquare. “The cannabis-related health and medical sector is a fast-growing market that offers attractive investment opportunities. The MedC listing enables dealers and advisors to offer this investment opportunity to their clients, and to execute investments efficiently and in a fully digitized way through our online platform.”

“MedC is well-positioned to deliver effective medical treatments for skin conditions in a highly underserviced market, and the funds raised from this joint campaign will help make that possible,” added Rebecca Kacaba, CEO of DealMaker. “We are honoured to be powering MedC in raising the capital needed to achieve rapid growth.”

“MedC’s capital raise is truly a noteworthy event,” concluded Jos Schmitt, President and CEO of NEO. “It marks the coming together of like-minded organizations, all of whom are on a relentless pursuit of innovation for the benefit of others. By harnessing the combined strength of DealMaker and DealSquare, powered by NEO, MedC gains exposure to a wider investor community, both here in Canada and abroad.”

To view MedC Biopharma’s private placement offering on DealSquare, click here. For direct investor investment, click here. The MedC Biopharma ticker is available under MEDCB on existing advisor order entry systems.

About MedC Biopharma

MedC Biopharma is a science-driven company focused on developing, producing, and delivering differentiated cannabinoid and other natural compound-containing products targeting the consumer, veterinary and medical skin & general health markets.

Connect with MedC Biopharma: Website | LinkedIn

About DealSquare

A joint initiative between NEO and Silver Maple Ventures, DealSquare, is Canada’s first centralized dealer platform for private placements, digitally connecting capital-raisers to investment dealers, their advisory networks, and their investors. With the complete roll-out of the platform in early 2020, DealSquare supports the entire private placement process: capital raisers publish their private placement opportunities; dealers complete their due diligence; and advisors electronically subscribe to a deal, with exempt securities seamlessly integrated into client accounts and back office systems utilizing NEO technology.

Connect with DealSquare: Website | LinkedIn | Twitter

About DealMaker

DealMaker is an innovative cloud-based platform for the capital raising and settlement of domestic and international private placements in capital markets, KYC and Fund Formation. DealMaker makes private placement transactions surprisingly pleasant, delivering speed, innovation, and efficiency to the global private capital markets. Financings using DealMaker close faster, with greater control over the process which creates a better experience. DealMaker strives for a simpler, cleaner way of doing things on one global platform.

Connect with DealMaker: Website | LinkedIn | Twitter

About NEO

NEO is a group of established fintech companies that provide capital markets infrastructure designed for and led by the industry. NEO’s competitive drive, innovation, and advocacy enable change for the better. The NEO Exchange is a progressive stock exchange that brings together investors and capital raisers within a fair, efficient, and service-oriented environment; and DealSquare, powered by NEO technology, is a platform that enables the distribution of financial assets not listed on a stock exchange in a way that reduces costs, minimizes operational risks, and improves the investor experience.

Connect with NEO: Website | Twitter | LinkedIn